Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer
G Bronte, S Bravaccini, E Bronte, MA Burgio… - Biological …, 2018 - Wiley Online Library
The identification of oncogenic driver mutations in non‐small‐cell lung cancer (NSCLC) has
led to the development of targeted drugs. Tyrosine kinase inhibitors (TKIs) directed against …
led to the development of targeted drugs. Tyrosine kinase inhibitors (TKIs) directed against …
[HTML][HTML] An immunomodulatory gallotanin-rich fraction from Caesalpinia spinosa enhances the therapeutic effect of anti-PD-L1 in melanoma
PD-1/PD-L1 pathway plays a role in inhibiting immune response. Therapeutic antibodies
aimed at blocking the PD-1/PD-L1 interaction have entered clinical development and have …
aimed at blocking the PD-1/PD-L1 interaction have entered clinical development and have …
An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
Y Huang, X Cuan, W Zhu, X Yang, Y Zhao… - International Journal of …, 2023 - mdpi.com
Inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR) using small-
molecule tyrosine kinase inhibitors (TKIs) or monoclonal antibodies is often ineffective in …
molecule tyrosine kinase inhibitors (TKIs) or monoclonal antibodies is often ineffective in …
[HTML][HTML] Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to …
L Xu, XH Xu, C Yuan, JY Zhang, X Tang… - Annals of …, 2018 - ncbi.nlm.nih.gov
Background Evaluation of the clinical efficacy and safety of icotinib in advanced
nonsquamous non-small cell lung cancer (NSCLC) patients with an unknown EGFR …
nonsquamous non-small cell lung cancer (NSCLC) patients with an unknown EGFR …
Liquid biopsy in cancer patients: the hand lens to investigate tumor evolution
A Russo, A Giordano, C Rolfo - Liquid Biopsy in Cancer Patients: The …, 2017 - Springer
In recent years the treatment of cancer patients has profoundly changed due to a better
comprehension of the biological processes underlying tumor development and progression …
comprehension of the biological processes underlying tumor development and progression …
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
E Gambale, C Carella, P Amerio, F Buttitta… - … Case Reports Journal, 2017 - Taylor & Francis
Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly …
(TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly …
Liquid Biopsies
M Palmieri, E Frullanti, R Alessandra - Technology in Practical …, 2020 - Springer
During the last years, given the need to identify a more accessible approach for tumor
genetic analysis as well as the advancements in next-generation sequencing …
genetic analysis as well as the advancements in next-generation sequencing …
Erlotinib en 2e ou 3e ligne pour les cancers bronchiques non à petites cellules sans mutation de l'EGFR: données en vie réelle
D Debieuvre, L Moreau, M Coudert, C Locher… - Revue des Maladies …, 2019 - Elsevier
Résumé Introduction Le bénéfice des inhibiteurs de la tyrosine kinase spécifiques de
l'EGFR, chez des patients sans mutation de l'EGFR, est controversé. Méthodes La survie de …
l'EGFR, chez des patients sans mutation de l'EGFR, est controversé. Méthodes La survie de …